Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis

Abstract

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.

Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study

“…Additionally, endogenous microglia are activated by day 40 PI in the TMEV model of chronic progressive disease . It has been shown that teriflunomide attenuates the response of activated macrophages and microglia in the EAE Myelin oligodendrocyte glycoprotein (MOG) disease model . In line with these findings, we found a numerically lower level of microglial activation within the CC in the teriflunomide‐treated group.…”

Moderate physical training attenuates perinatal low-protein-induced spleen lymphocyte apoptosis in endotoxemic adult offspring rats

“…Then, the suspension was incubated for 30 min with an antibody cocktail for T/B/NK cells identification (Rat T/B/ NK Cell Cocktail, BD Biosciences, San Jose, USA), protected from light at 4 °C. The cell suspensions were washed two more times with cytometry buffer and then analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, USA) [26].…”

Teriflunomide for multiple sclerosis in real-world setting

“…1,2 As rapidly proliferating lymphocytes are in high demand of pyrimidine, this reversible inhibition of DHODH limits expansion of stimulated lymphocytes in the periphery and consequently within the central nervous system. 3,4 Resting and slowly dividing cells are less affected, because the DHODH-independent salvage pathway provides enough pyrimidine. 5 This differential effect may be important to maintain protective immunity and a beneficial adverse event (AE) profile.…”